These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 31704279)

  • 21. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Operability and Pathological Response of Non-Small Cell Lung Cancer (NSCLC) after Neoadjuvant Therapy with Immune Checkpoint Inhibition].
    Lücke E; Ganzert C; Föllner S; Wäsche A; Jechorek D; Schoeder V; Walles T; Genseke P; Schreiber J
    Pneumologie; 2020 Nov; 74(11):766-772. PubMed ID: 32820489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aggravation of depigmentation for a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: case report.
    Xu Y; Cai Y; Zu J; Wang X; Wang Y; Sun C; Guo Y; Shao G; Yang Z; Qiu S; Ma K
    Immunotherapy; 2020 Feb; 12(3):175-181. PubMed ID: 32064977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune Checkpoint Inhibitor-Induced Myasthenia Gravis in a Patient with Advanced NSCLC and Remote History of Thymoma.
    Lara MS; Afify A; Ellis MP; Phan CT; Richman DP; Riess JW
    Clin Lung Cancer; 2019 Jul; 20(4):e489-e491. PubMed ID: 31085042
    [No Abstract]   [Full Text] [Related]  

  • 25. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
    Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
    Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytokine Release Syndrome with Pseudoprogression in a Patient with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab.
    Kogure Y; Ishii Y; Oki M
    J Thorac Oncol; 2019 Mar; 14(3):e55-e57. PubMed ID: 30782385
    [No Abstract]   [Full Text] [Related]  

  • 27. Treatment of steroid-resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report.
    Miao K; Xu Y; Xu W; Zhang Y; Xu Y; Tian X; Zhang L
    Thorac Cancer; 2021 Aug; 12(15):2214-2216. PubMed ID: 34145962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyperprogressive Disease in Lung Cancer with Transformation of Adenocarcinoma to Small-cell Carcinoma during Pembrolizumab Therapy.
    Okeya K; Kawagishi Y; Muranaka E; Izumida T; Tsuji H; Takeda S
    Intern Med; 2019 Nov; 58(22):3295-3298. PubMed ID: 31327828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful Retreatment Using Pembrolizumab for Non-small-cell Lung Cancer After Severe Immune-related Hepatitis: A Case Report.
    Kobayashi K; Nakachi I; Mitsuishi A; Arai D; Sakurai K; Masaki K; Chiyotani A; Takahashi H; Tahara T; Soejima K
    Clin Lung Cancer; 2020 Jan; 21(1):e30-e32. PubMed ID: 31699508
    [No Abstract]   [Full Text] [Related]  

  • 30. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Dafni U; Tsourti Z; Vervita K; Peters S
    Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyperprogression after first dose of immunotherapy in a patient with radioresistant metastasis from nonsmall cell lung cancer.
    Bosch-Barrera J; Oliva E; Sais E; Vásquez CA; Roselló A; Menéndez JA
    Anticancer Drugs; 2019 Nov; 30(10):1067-1070. PubMed ID: 31567311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis.
    Chen Y; Hu J; Bu F; Zhang H; Fei K; Zhang P
    BMC Cancer; 2020 Jul; 20(1):707. PubMed ID: 32727409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pulmonary complications of tyrosine kinase inhibitors and immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Gupta K; Uchel T; Karamian G; Loschner A
    Cancer Treat Res Commun; 2021; 28():100439. PubMed ID: 34333246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients.
    Zhai X; Zhang J; Tian Y; Li J; Jing W; Guo H; Zhu H
    Cancer Biol Med; 2020 Aug; 17(3):599-611. PubMed ID: 32944393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anlotinib succeeded in rescue therapy for hyperprogression induced by immune checkpoint inhibitors: a case report.
    Chen L; Liu D; Zhang Y; Jia Y; Zhao X; Liu M; Kong T
    Immunotherapy; 2023 Jun; 15(9):631-639. PubMed ID: 37020412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan.
    Hsu JC; Lin JY; Hsu MY; Lin PC
    PLoS One; 2018; 13(8):e0202725. PubMed ID: 30142174
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer.
    Bar J; Ofek E; Barshack I; Gottfried T; Zadok O; Kamer I; Urban D; Perelman M; Onn A
    Lung Cancer; 2019 Dec; 138():109-115. PubMed ID: 31683093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature.
    Cosimati A; Rossi L; Didona D; Forcella C; Didona B
    J Oncol Pharm Pract; 2021 Apr; 27(3):727-733. PubMed ID: 32772795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severe infusion reaction due to nivolumab: A case report.
    Kumari S; Yun J; Soares JR; Ding PN
    Cancer Rep (Hoboken); 2020 Jun; 3(3):e1246. PubMed ID: 32671983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
    Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.